Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Esther RajaveluSEE REMARKS | Spero TherapeuticsSPRO | Open-market sale | 05/04 | 05/06 | 25,240 sh | $2.51 | $63,352.4 | −2.5% |
Spero TherapeuticsSPRO | Open-market sale | 02/06 | 02/09 | 18,652 sh | $2.36 | $44,018.72 | −2.5% | |
Spero TherapeuticsSPRO | Open-market sale | 02/06 | 02/09 | 87,917 sh2 trades | $2.36avg. | $207,484.12 | −8.0% | |
Spero TherapeuticsSPRO | Open-market sale | 02/02–02/04 | 02/05 | 46,586 sh3 trades | $2.17avg. | $101,174.6 | −5.8% | |
Esther RajaveluSEE REMARKS | Spero TherapeuticsSPRO | Open-market sale | 02/02 | 02/04 | 18,442 sh | $2.20 | $40,572.4 | −1.6% |
Esther RajaveluSEE REMARKS | Spero TherapeuticsSPRO | Open-market sale | 25/11/07 | 25/11/12 | 40,270 sh | $2.37 | $95,439.9 | −4.4% |
Ankit MahadeviaDirector | Spero TherapeuticsSPRO | Open-market sale | 25/08/28 | 25/09/03 | 6,572 sh | $1.97 | $12,946.84 | −0.9% |
Spero TherapeuticsSPRO | Open-market sale | 25/08/28 | 25/09/03 | 1,695 sh | $1.97 | $3,339.15 | −0.2% | |
Spero TherapeuticsSPRO | Open-market sale | 25/02/05 | 25/02/05 | 69,219 sh2 trades | $0.78avg. | $53,990.82 | −9.1% | |
Spero TherapeuticsSPRO | Open-market sale | 25/02/05 | 25/02/05 | 155,333 sh3 trades | $0.78avg. | $121,159.74 | −8.2% | |
Spero TherapeuticsSPRO | Open-market sale | 25/02/05 | 25/02/05 | 56,537 sh3 trades | $0.78avg. | $44,098.86 | −7.1% | |
Esther RajaveluCFO & Cbo | Spero TherapeuticsSPRO | Open-market sale | 25/02/05 | 25/02/05 | 20,689 sh | $0.78 | $16,137.42 | −2.8% |
Spero TherapeuticsSPRO | Open-market sale | 24/11/07–24/11/08 | 24/11/12 | 40,596 sh2 trades | $1.31avg. | $53,008.31 | −9.7% | |
Ankit MahadeviaDirector | Spero TherapeuticsSPRO | Open-market sale | 24/08/27 | 24/08/29 | 5,912 sh | $1.35 | $7,981.2 | −0.8% |
Sath ShuklaCEO & President | Spero TherapeuticsSPRO | Open-market sale | 24/08/27 | 24/08/29 | 2,757 sh | $1.35 | $3,721.95 | −0.2% |
Spero TherapeuticsSPRO | Open-market sale | 24/08/27 | 24/08/29 | 2,213 sh | $1.35 | $2,987.55 | −0.4% | |
Spero TherapeuticsSPRO | Open-market sale | 24/08/02–24/08/05 | 24/08/06 | 32,441 sh2 trades | $1.31avg. | $42,645.71 | −2.8% | |
Spero TherapeuticsSPRO | Open-market sale10b5-1 plan | 24/02/02–24/02/05 | 24/02/05 | 75,994 sh2 trades | $1.42avg. | $107,719.22 | −6.1% | |
Tamara L. JosephChief Legal Officer | Spero TherapeuticsSPRO | Open-market sale | 24/02/02 | 24/02/05 | 30,906 sh | $1.37 | $42,341.22 | −5.5% |
Ankit MahadeviaDirector | Spero TherapeuticsSPRO | Open-market sale | 24/02/02 | 24/02/05 | 63,795 sh | $1.37 | $87,399.15 | −7.9% |